PHRRF Stock Performance, Insider Transaction and News

PHRRF - PHARMATHER HOLDINGS LTD

Market Cap	11.07M	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-	Forward P/E	-	EPS next Y	-	50D Avg Chg	14.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	31.00%
Dividend	N/A	Price/Book	1.57	EPS next 5Y	-	52W High Chg	-34.00%
Recommedations	-	Quick Ratio	-	Shares Outstanding	88.17M	52W Low Chg	239.00%
Insider Own	18.69%	ROA	-	Shares Float	-	Beta	-
Inst Own	0.06%	ROE	-	Shares Shorted/Prior	-/-	Price	0.13
Gross Margin	-	Profit Margin	-	Avg. Volume	213,419	Target Price	-
Oper. Margin	-	Earnings Date	-	Volume	284,545	Change	16.51%

Healthcare | Biotechnology | Canada

About PHARMATHER HOLDINGS LTD

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS. The company also holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology; and a license agreement with Gesval SA, as well as valuation and exclusive option agreement with Case Western Reserve University for development and commercialization for the intellectual property of ketamine for the treatment of Rett syndrome. PharmaTher Holdings Ltd. was incorporated in 2019 and is headquartered in Toronto, Canada.

PHARMATHER HOLDINGS LTD News

11/13/24	PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
11/12/24	Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
10/23/24	PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
10/22/24	TSX Penny Stocks To Consider In October 2024
09/04/24	PharmaTher Announces Update on FDA New Drug Application for Ketamine
08/28/24	PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
08/21/24	PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
08/19/24	PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
05/15/24	PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
05/10/24	PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
05/01/24	PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
03:00 PM	PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
04/02/24	Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
02/21/24	PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
01/14/24	Weekly Roundup on the Cannabis Sector & Psychedelic Sector
01/10/24	PharmaTher Provides Update for Expected FDA Approval of Ketamine

PHRRF Chatroom

jcc51 Posted - 2 days ago

$PHRRF all psychs are booming, us next?

Trader1317 Posted - 3 days ago

$PHRRF what do we see as a price target for this stock?

MikeProZ Posted - 3 days ago

$PHRRF good looking chart here.

MikeProZ Posted - 4 days ago

$PHRRF #BreakingNews PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application https://finance.yahoo.com/news/pharmather-announces-post-complete-response-130000246.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

BaronXXII Posted - 5 days ago

$RVVTF RFK knows about psychedelics. Anything with psilocybin or ketamine should hit prime time. Watch for Big Pharma to try to take out little guys (micro caps) so they can quash the IP... $PFE $MRNA $PHRRF $GNLX

MikeProZ Posted - 6 days ago

$PHRRF

Tonyboner Posted - 6 days ago

$PHRRF low on cash, need to raise at some stage catalyst for next year's play :)

jcc51 Posted - 1 week ago

@DFV_ShortSlayer @PsychedStocks $PHRRF as another ketamine play

jcc51 Posted - 1 week ago

$PHRRF RFK jr already saying he wants to lessen regulation on psychedelics

dcajic2 Posted - 1 week ago

$PHRRF It’s a lotto ticket but holding many shares. It should finally get fda approval in the coming months

ilovecleanair Posted - 10/28/24

$PHRRF OK Filled at .1512 PHRRF PHARMATHER HLDGS LTD Filled Buy 30,005 Limit $0.155 Day $0.1512 $0.1475 $0.1512 $0.155 $0.1512 11:23 AM 10/28/2024 11:23 AM 10/28/2024 Filled at .1588 PHRRF PHARMATHER HLDGS LTD Filled Buy 119,995 Limit $0.1598 Day $0.1588a $0.1475 $0.1512 $0.155 $0.1512 11:20 AM 10/28/2024 11:20 AM 10/28/2024

wavychaser Posted - 10/23/24

Let's see some $PHRRF insider buying!

andysch Posted - 10/23/24

$PHRRF Why are the FDA only making additional demands so close to the end date?

Woooehoo Posted - 10/23/24

$PHRRF so neutral lmao

MikeProZ Posted - 10/23/24

$PHRRF news out - PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application

Cmon11 Posted - 10/23/24

$PHRRF

jcc51 Posted - 10/23/24

$PHRRF updated PR and slide deck seems to infer approval won’t be until 2025 at this point.

MJ41 Posted - 10/23/24

$PHRRF what a POS fake company

MikeProZ Posted - 10/22/24

$PHRRF looking for support imo

MikeProZ Posted - 10/21/24

$PHRRF nice

trout290zzaam Posted - 10/21/24

$PHRRF volume

trout290zzaam Posted - 10/21/24

$PHRRF Let the run up begin.

MikeProZ Posted - 10/21/24

$PHRRF Trending up! $DRUG $XBI

Polecatt613 Posted - 10/19/24

$PHRRF fuk again

Retired30 Posted - 4 weeks ago

$PHRRF nice run-up during power hour! Hopefully this is the beginning of a nice run up into the Oct. 29th GDUFA. Company has already had a CRL and there has been no new feedback from FDA so odds of approval are good. With only 18m market cap price can move quick. Almost 5x volume today compared to last 7 days! Remember this is Ketamine related so that buzz word could also spur interest.

lawrence4270 Posted - 4 weeks ago

$PHRRF My first buy today at .19 ending the day solid...

jcc51 Posted - 4 weeks ago

$PHRRF 5 new watchers here. This pop up on someone scanner?

wavychaser Posted - 1 month ago

Interested in $PHRRF, going to do some extra DD and look for a great entry ;D Still holding $KULR long and strong as well ;D

MikeProZ Posted - 1 month ago

$PHRRF Dip buy opp

jcc51 Posted - 1 month ago

$PHRRF 50 MA crossing the 200 MA is lining up for the fda approval catalyst in 9 trading days